Target Audience: This complimentary activity is intended for physicians and podiatrists.
Completion Time: The estimated time to complete this activity is two hours.
Objectives: Upon completion of this educational activity, participants should be able to:
• discuss key elements of the protocol for the SIDESTEP study and how they contributed to the study’s clinical outcomes;
• compare the clinical response rates reported for ertapenem and piperacillin/tazobactam in the SIDESTEP study;
• compare and contrast the spectrum of activity for ertapenem and piperacillin/tazobactam;
• describe the wound scoring system that was utilized in the SIDESTEP study;
• discuss common pathogens in diabetic foot infections; and
• discuss the role of appropriate culturing with diabetic foot wounds.
Disclosure Policy: All faculty participating in continuing education programs sponsored by the North American Center for Continuing Medical Education (NACCME) are expected to disclose to the meeting audience any real or apparent conflict(s) of interest related to the content of their presentation. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.
Dr. Armstrong has disclosed that he has received grant/research support from Merck and Pfizer.
Dr. Joseph has disclosed that he is a consultant and a member of the Speakers’ Bureau for Merck and Pfizer.
Dr. Lavery has disclosed that he has no significant financial relationship with any organization that could be perceived as a real or apparent conflict of interest in the context of this discussion.
Dr. Lipsky has disclosed that he has received grant/research support and is a consultant for Pfizer, Merck and Cubist.
Dr. Sheehan has disclosed that he is a member of the Speakers’ Bureau for Merck.
Participation: Read the supplement, take, submit and pass the post-test by June 30, 2007.
Release Date: April 1, 2006
Expiration Date: June 30, 2007
Commercial Support Disclosure: This activity is supported by an educational grant from Merck & Co.
Accreditation Statements:
MD/DO: This activity is sponsored by the North American Center for Continuing Medical Education (NACCME). NACCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. NACCME designates this continuing medical education activity for a maximum of two category 1 credit(s) toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity. This activity has been planned and produced in accordance with the ACCME Essential Areas and Policies.
Podiatrists: The North American Center for Continuing Medical Education (NACCME) is approved by the Council on Podiatric Medical Education as a sponsor of continuing education in podiatric medicine. This program is approved for 2 continuing education contact hour(s) or 0.2 CEU(s).
Off-Label/Unapproved Usage Disclosure: This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Neither NACCME nor Merck & Co. recommends the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Sponsor: North American Center for Continuing Medical Education (NACCME).
How To Obtain Education Credits: Participants must score at least 70 percent on the questions and successfully complete the entire evaluation form (found on page 23), make a copy of the entire evaluation form and send it to the address listed below. Certificates will be mailed to those who successfully complete the learning assignment by June 30, 2007.
Fax or mail the completed form to:
Trish Levy, Director, Medical Education
North American Center for Continuing Medical Education
(NACCME)
83 General Warren Boulevard, Suite 100
Malvern, PA 19355
Fax: (610) 560-0502 |
